Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Biomarkers for EGFR-antagonist response: in the genes and on the genes!

Easwaran H, Baylin SB.

Clin Cancer Res. 2012 Apr 15;18(8):2121-3. doi: 10.1158/1078-0432.CCR-12-0157. Epub 2012 Feb 27.

2.

DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.

Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, Iniguez L, Soriano R, Huw L, Stern H, Modrusan Z, Seshagiri S, Hampton GM, Amler LC, Bourgon R, Yauch RL, Shames DS.

Clin Cancer Res. 2012 Apr 15;18(8):2360-73. doi: 10.1158/1078-0432.CCR-11-2635-T. Epub 2012 Jan 19.

3.

Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.

Fujii A, Harada T, Iwama E, Ota K, Furuyama K, Ijichi K, Okamoto T, Okamoto I, Takayama K, Nakanishi Y.

Cancer Genet. 2015 May;208(5):271-8. doi: 10.1016/j.cancergen.2014.12.005. Epub 2015 Jan 6.

PMID:
25682017
4.

Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.

Suzuki M, Wada H, Yoshino M, Tian L, Shigematsu H, Suzuki H, Alaa M, Tamura H, Fujiwara T, Nagato K, Motohashi S, Moriya Y, Hoshino H, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, Yoshino I.

Ann Surg Oncol. 2010 Mar;17(3):878-88. doi: 10.1245/s10434-009-0739-3. Epub 2009 Oct 16.

PMID:
19841986
5.

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.

Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.

Oncol Rep. 2013 May;29(5):1975-82. doi: 10.3892/or.2013.2298. Epub 2013 Feb 21.

PMID:
23440266
7.

Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR.

Ren S, Su C, Wang Z, Li J, Fan L, Li B, Li X, Zhao C, Wu C, Hou L, He Y, Gao G, Chen X, Ren J, Li A, Xu G, Zhou X, Zhou C, Schmid-Bindert G.

Int J Cancer. 2014 Dec 15;135(12):2962-71. doi: 10.1002/ijc.28925. Epub 2014 May 7.

8.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

9.

High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.

Stone E, Allen HA, Saghaie T, Abbott A, Daniel R, Mead RS, Kohonen-Corish M, Plit M, Morgan L.

Intern Med J. 2014 Dec;44(12a):1188-92. doi: 10.1111/imj.12587.

PMID:
25228365
10.

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.

Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.

Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.

PMID:
25617986
11.

Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.

Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, Gazdar AF, Fujisawa T.

Cancer. 2006 May 15;106(10):2200-7.

12.

Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer.

Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, Shibuya K, Iizasa T, Hiroshima K, Nakatani Y, Gazdar AF, Fujisawa T.

Clin Cancer Res. 2007 Oct 15;13(20):6087-92.

13.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Review.

14.

The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer.

Willmore-Payne C, Holden JA, Wittwer CT, Layfield LJ.

J Biomol Tech. 2008 Jul;19(3):217-24.

15.

Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy.

Cui Y, Xu J, Xin L, Tian Y, Zhan Z, Qi D.

J Cancer Res Ther. 2015 Aug;11 Suppl 1:C80-3. doi: 10.4103/0973-1482.163847.

16.

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.

Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, Tanaka S, Suga T, Saito R, Ishizuka T, Dobashi K, Minna JD, Nakajima T, Mori M.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22.

17.

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T.

J Thorac Oncol. 2007 May;2(5):430-9.

18.

Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.

Peters MJ, Bowden JJ, Carpenter P, Lewis J, Solomon B.

Intern Med J. 2014 Jun;44(6):575-80. doi: 10.1111/imj.12449.

PMID:
24720523
19.

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD.

Cancer Res. 2005 Oct 15;65(20):9455-62.

20.

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.

Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y.

Lung Cancer. 2005 Dec;50(3):385-91. Epub 2005 Sep 2.

PMID:
16140420

Supplemental Content

Support Center